Melanoma Clinical Trials in Seattle

Showing 21-40 of 58 trials

Intrahepatic Delivery of SD-101 by Pressure-Enabled Regional Immuno-oncology (PERIO), With Checkpoint Blockade in Adults With Metastatic Uveal Melanoma

NCT04935229

This study is an open-label, phase 1/1b study of the pressure-enabled hepatic artery infusion of SD-101, a TLR 9 agonist, alone or in combination with intravenous checkpoint blockade in adults with metastatic uveal melanoma.

Metastatic Uveal Melanoma in the Liver

TriSalus Life Sciences, Inc.67 participantsStarted Aug 2021

Los Angeles, California, United States • Stanford, California, United States • Denver, Colorado, United States +7 more locations

ACTIVE_NOT_RECRUITINGPHASE1/PHASE2< 1 mile

Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLC

NCT04140526

This is a First-in-Human Phase IA/IB/II open label dose escalation study of intravenous (IV) administration of ONC-392, a humanized anti-CTLA4 IgG1 monoclonal antibody, as single agent and in combination with pembrolizumab in participants with advanced or metastatic solid tumors and non-small cell lung cancers.

Non Small Cell Lung CancerAdvanced Solid TumorMetastatic Melanoma+16 more

OncoC4, Inc.733 participantsStarted Sep 2020

Springdale, Arkansas, United States • Davis, California, United States • Downey, California, United States +34 more locations

Intrahepatic Delivery of SD-101 by Pressure-Enabled Regional Immuno-oncology (PERIO), With Checkpoint Blockade in Adults With Metastatic Uveal Melanoma

Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLC

Melanoma Trials in Other Cities

Efficacy Study of Nivolumab Compared to Ipilimumab in Prevention of Recurrence of Melanoma After Complete Resection of Stage IIIb/c or Stage IV Melanoma

Testing the Addition of an Experimental Medication MK-3475 (Pembrolizumab) to Usual Anti-Retroviral Medications in Patients With HIV and Cancer

Safety Study of SEA-CD40 in Cancer Patients

Therapeutic Autologous Lymphocytes, Aldesleukin, and Denileukin Diftitox in Treating Patients With Stage III-IV Melanoma

Milademetan in Advanced/Metastatic Solid Tumors

Efficacy, Safety, and Tolerability of Gebasaxturev (V937) Administered Intravenously or Intratumorally With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone in Participants With Advanced/Metastatic Melanoma (V937-011)

Multi-center Phase I/IIa Trial of an Autologous Tumor Lysate (TL) + Yeast Cell Wall Particles (YCWP) + Dendritic Cells (DC) Vaccine in Addition to Standard of Care Checkpoint Inhibitor of Choice in Metastatic Melanoma Patients With Measurable Disease.

Interleukin-21 in Treating Patients With Metastatic or Recurrent Malignant Melanoma

Nicotinamide Chemoprevention for Keratinocyte Carcinoma in Solid Organ Transplant Recipients - Pivotal Trial

Substudy 02C: Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents or Pembrolizumab Alone in Participants With Stage III Melanoma Who Are Candidates for Neoadjuvant Therapy (MK-3475-02C/KEYMAKER-U02)

A Study of SEA-CD40 Given With Other Drugs in Cancers

A Study of Ladiratuzumab Vedotin in Advanced Solid Tumors

MGD019 DART® Protein in Unresectable/Metastatic Cancer

Study of ADCT-301 in Patients With Selected Advanced Solid Tumors

A Study of INCMGA00012 in Participants With Selected Solid Tumors (POD1UM-203)

Phase I/II Study of PDR001 in Patients With Advanced Malignancies

ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation

Percutaneous Hepatic Perfusion in Patients With Hepatic-dominant Ocular Melanoma

Other Conditions in Seattle